Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients

Table 4 CD4+ monthly mortality rate

	> 500 (%)	350–500 (%)	200–350 (%)	100–200 (%)	50–100 (%)	0–50 (%)
Normal mortality	0.0002
Adjusted natural mortality	− 0.0005
HIV mortality (raw)	0.7000	1.2000	1.8000	8.0000	8.0000	8.0000
HIV mortality (monthly adjustment)	0.0585	0.1006	0.1513	0.6924	0.6924	0.6924
Average HIV mortality	0.1850
AOI mortality rate (monthly)
m	0.041	1.020	4.476	0.960	3.100	3.700
Fungal	0.106	0.331	0.348	0.135	0.591	1.123
Protozoal	0.003	0.009	0.504	0.067	0.140	0.270
Viral	0.006	0.013	0.696	0.214	0.523	1.857
Other OI	0.047	0.087	0.224	0.716	2.460	3.940
AOI final mortality (monthly)	0.009	0.065	0.364	0.105	0.326	0.530
Average AOI rate	0.181
Used in the model	0.067	0.165	0.515	0.796	1.018	1.222
Monthly CD4+ mortality rate	0.067	0.165	0.515	0.796	1.018	1.222

Regarding the correction for all-cause mortality, a standardised mortality ratio by CD4+ cell count was applied as derived by Lewden et al. [35]

ISSN: 1478-7547